SAB Biotherapeutics (SABS) News Today $3.88 +0.62 (+19.02%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)October 15, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationOctober 10, 2024 | msn.comSAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash WiselySeptember 23, 2024 | finance.yahoo.comSAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare ConferenceSeptember 13, 2024 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from OppenheimerSeptember 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Vor Biopharma (VOR)September 11, 2024 | markets.businessinsider.comSAB BIO to Present at the European Association for the Study of Diabetes 60th Annual MeetingSeptember 4, 2024 | globenewswire.comBuy Rating on SAB Biotherapeutics: Promising Developments in Type 1 Diabetes TreatmentAugust 29, 2024 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 10, 2024 | finanznachrichten.deAnalysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and SAB Biotherapeutics (SABS)August 10, 2024 | markets.businessinsider.comSABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024August 9, 2024 | investorplace.comSAB BIO Announces Second Quarter 2024 Financial Results and Provides Company UpdatesAugust 8, 2024 | globenewswire.comSAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 7, 2024 | finanznachrichten.deSAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 DiabetesAugust 5, 2024 | globenewswire.comEx-Wells Fargo investment banker named CFO of pharma companyAugust 1, 2024 | bizjournals.comSAB BIO Appoints Lucy To as Chief Financial OfficerJuly 31, 2024 | globenewswire.comSAb Biotherapeutics Rebrands as SAB BIOJune 20, 2024 | globenewswire.comSAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific SessionsJune 18, 2024 | globenewswire.comSAB Biotherapeutics Announces Departure of Chief Financial OfficerMay 30, 2024 | globenewswire.comPharma company moves headquarters from Midwest to Miami BeachMay 25, 2024 | bizjournals.comSAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics: Strong Buy Rating on Robust Financials and Promising Diabetes Drug DevelopmentMay 21, 2024 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 21, 2024 | finanznachrichten.deSAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 DiabetesMay 21, 2024 | markets.businessinsider.comFDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB BiotherapeuticsMay 21, 2024 | globenewswire.comSAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesMay 20, 2024 | globenewswire.comSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsMay 6, 2024 | globenewswire.comSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36April 17, 2024 | msn.comSAB Leaps on Completing Latest CohortApril 16, 2024 | msn.comSAB Biotherapeutics Provides SAB-142 Trial UpdateApril 16, 2024 | globenewswire.comSAB Biotherapeutics to Present at INNODIA Annual MeetingApril 8, 2024 | globenewswire.comSAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy RatingApril 4, 2024 | markets.businessinsider.comSAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceApril 4, 2024 | globenewswire.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsApril 1, 2024 | finance.yahoo.comSAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsMarch 29, 2024 | globenewswire.comSAB Collaborates With Naval Medical Research To Develop Potential Influenza Treatment; Stock DropsMarch 25, 2024 | markets.businessinsider.comSAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentMarch 25, 2024 | globenewswire.comSAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceFebruary 23, 2024 | globenewswire.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 8, 2024 | finance.yahoo.comSAB Biotherapeutics Names Samuel Reich Chief ExecutiveFebruary 2, 2024 | marketwatch.comSAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEOFebruary 2, 2024 | markets.businessinsider.comSAB Biotherapeutics Announces Executive Leadership ChangeFebruary 2, 2024 | finance.yahoo.comTrading was temporarily halted for "SABS" at 09:01 AM with a stated reason of "LULD pause."January 29, 2024 | marketbeat.comSAB Biotherapeutics, Inc.: SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 24, 2024 | finanznachrichten.deSAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementJanuary 23, 2024 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)January 8, 2024 | markets.businessinsider.comIndividual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last weekJanuary 5, 2024 | finance.yahoo.comTrading was temporarily halted for "SABS" at 07:01 PM with a stated reason of "News pending."January 5, 2024 | marketbeat.com Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Bezos, & Congress Are Piling Into This One Sector (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market… Click here for the details SABS Media Mentions By Week SABS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SABS News Sentiment▼-1.000.38▲Average Medical News Sentiment SABS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SABS Articles This Week▼01▲SABS Articles Average Week Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGLS News Today AGEN News Today FBIO News Today CRIS News Today BOLT News Today MTEM News Today AMGN News Today VRTX News Today GILD News Today REGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SABS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
